PRKCA and myeloid sarcoma: The difference was somewhat larger in affected individuals (Ct = 25.5 ± 0.39 [SD] in heterozygotes and 27.0 ± 0.27 [SD] in homozygotes), which translates to 3-fold less PRKCA transcript in MS patients with two copies of the putative risk allele.